CYTOMX THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months Low: CYTOMX THERAPEUTICS INC. - COMMON STOCK

28 10 2024 08:30:57 提供 NetDania Notify

NetDania - New 12 months Low: CYTOMX THERAPEUTICS INC. - COMMON STOCK

25 10 2024 08:27:19 提供 NetDania Notify

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

09 9 2024 05:00:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming September Investor Conferences

04 9 2024 05:00:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

08 8 2024 13:10:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

01 8 2024 05:00:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

18 6 2024 05:00:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

17 6 2024 13:15:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

22 5 2024 13:05:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

16 5 2024 13:15:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

08 5 2024 13:10:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

08 5 2024 13:10:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

07 5 2024 13:15:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

01 5 2024 05:00:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

08 4 2024 05:00:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

03 4 2024 05:00:01 提供 Nasdaq GlobeNewswire

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

21 3 2024 05:00:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

18 3 2024 05:00:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

11 3 2024 13:10:00 提供 Nasdaq GlobeNewswire

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

04 3 2024 05:00:00 提供 Nasdaq GlobeNewswire